PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+19.43%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.46%
AUM
$2.97B
AUM Growth
-$467M
(-14%)
Cap. Flow
-$158M
Cap. Flow
% of AUM
-5.33%
Top 10 Holdings %
Top 10 Hldgs %
46.1%
Holding
105
New
9
Increased
22
Reduced
25
Closed
10
Top Buys
| 1 |
Immunovant
IMVT
|
$49.6M |
| 2 |
argenx
ARGX
|
$40.1M |
| 3 |
Apogee Therapeutics
APGE
|
$38.9M |
| 4 |
Revolution Medicines
RVMD
|
$36.6M |
| 5 |
Tango Therapeutics
TNGX
|
$27.2M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$74M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$68.3M |
| 3 |
Vir Biotechnology
VIR
|
$48M |
| 4 |
Amylyx Pharmaceuticals
AMLX
|
$40M |
| 5 |
Illumina
ILMN
|
$27.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Revolution Medicines
RVMD
$7.4B
| $36.6M | 1.22% |
+1,321,795
| New | +$36.6M |
|
|
SWTX
27
DELISTED
SpringWorks Therapeutics
SWTX
| $35.2M | 1.17% |
1,520,416
-17,015
| -1% | -$393K |
|
28
Axsome Therapeutics
AXSM
$6.11B
| $33.7M | 1.12% |
481,649
+210,156
| +77% | +$14.7M |
|
29
Harmony Biosciences
HRMY
$2.13B
| $32.6M | 1.09% |
996,306
+104,936
| +12% | +$3.44M |
|
30
RAPT Therapeutics
RAPT
$192M
| $31.9M | 1.06% |
240,082
-45,980
| -16% | -$6.11M |
|
31
Rocket Pharmaceuticals
RCKT
$351M
| $31.1M | 1.04% |
1,517,467
+349,104
| +30% | +$7.15M |
|
32
Nautilus Biotechnolgy
NAUT
$82.5M
| $28.8M | 0.96% |
9,111,151
| – | – |
|
33
Acrivon Therapeutics
ACRV
$41.8M
| $28.8M | 0.96% |
3,007,858
| – | – |
|
|
34
Tango Therapeutics
TNGX
$738M
| $27.2M | 0.91% |
+2,418,968
| New | +$27.2M |
|
35
ADMA Biologics
ADMA
$4B
| $25M | 0.83% |
6,984,319
-4,915,936
| -41% | -$17.6M |
|
36
Treace Medical Concepts
TMCI
$453M
| $24M | 0.8% |
1,834,060
-383,190
| -17% | -$5.02M |
|
37
Tarsus Pharmaceuticals
TARS
$2.41B
| $23M | 0.77% |
1,296,416
| – | – |
|
38
Cogent Biosciences
COGT
$1.82B
| $22.5M | 0.75% |
2,309,470
-350,000
| -13% | -$3.41M |
|
39
Sarepta Therapeutics
SRPT
$1.92B
| $22.1M | 0.74% |
182,720
+101,646
| +125% | +$12.3M |
|
40
Mirum Pharmaceuticals
MIRM
$3.74B
| $21.2M | 0.71% |
672,042
+70,476
| +12% | +$2.23M |
|
41
Orchestra BioMed
OBIO
$144M
| $21.2M | 0.71% |
2,432,089
+379,221
| +18% | +$3.31M |
|
42
Xenon Pharmaceuticals
XENE
$2.97B
| $21.1M | 0.7% |
617,500
-605,877
| -50% | -$20.7M |
|
43
Verrica Pharmaceuticals
VRCA
$50.6M
| $19.6M | 0.65% |
503,898
| – | – |
|
44
Biohaven
BHVN
$1.68B
| $19.6M | 0.65% |
751,820
+431,000
| +134% | +$11.2M |
|
45
Madrigal Pharmaceuticals
MDGL
$9.72B
| $18.2M | 0.61% |
124,637
-178,350
| -59% | -$26M |
|
46
Neurocrine Biosciences
NBIX
$13.6B
| $17.9M | 0.6% |
159,242
+59,192
| +59% | +$6.66M |
|
47
Protagonist Therapeutics
PTGX
$3.6B
| $17.6M | 0.59% |
1,054,273
-415,488
| -28% | -$6.93M |
|
|
RYZB
48
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $17.2M | 0.58% |
+776,805
| New | +$17.2M |
|
49
Cabaletta Bio
CABA
$139M
| $17.2M | 0.58% |
1,132,491
-412,509
| -27% | -$6.28M |
|
50
Relay Therapeutics
RLAY
$698M
| $16.3M | 0.55% |
1,943,097
| – | – |
|